Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.
While manual segmentation of lesions and comparisons of PET and SPECT images would take hours to ascertain whole-body tumor burden, an emerging artificial intelligence (AI)-enabled software may provide significantly enhanced diagnostic efficiency.
The updated LesionID Pro software, which will be introduced by GE HealthCare at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference, features automated zero-click pre-processing of PET and SPECT images.
Powered by enhanced AI algorithms and designed with input from leading theranostics clinicians, the new LesionID Pro software, which reportedly offers automated analysis of whole-body tumor burden, is slated to be introduced at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference. (Image courtesy of GE HealthCare.)
Powered by enhanced AI algorithms and designed with input from leading theranostics clinicians, the new LesionID Pro offers automated analysis of whole-body tumor burden, according to GE HealthCare and MIM Software, the developers of LesionID Pro.
“We designed our portfolio of precision care solutions to evolve with healthcare system needs and help support a patient’s entire care journey – from the imaging equipment needed for a noninvasive look at a patient’s anatomy and treatment monitoring, to novel radiopharmaceuticals used to diagnose and monitor disease and the systems required to produce them, to the software optimized to enable data-driven decision-making. In the hands of clinicians, these tools help advance the global practice of personalized medicine and help improve patient outcomes,” noted Jean-Luc Procaccini, the president and CEO of molecular Imaging and computed tomography at GE HealthCare.
GE HealthCare noted that LesionID Pro with automated pre-click processing is pending 510(k) clearance by the Food and Drug Administration (FDA).
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
CT Perfusion Study Shows Enhanced Detection of Medium Vessel Occlusions with Emerging AI Software
May 21st 2025The Rapid CTP AI software offered 23 percent greater detection of medium vessel occlusions in comparison to the Viz CTP AI software, according to research presented at the European Stroke (Organization) Conference (ESOC).
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.